Axovant's seizure treatment spinoff has closed its series A round having received more than $133m in equity funding and $74.5m in project financing.
Arvelle Therapeutics, a Switzerland-based central nervous system (CNS) disorder drug developer spun off from pharmaceutical company Axovant, announced on Tuesday it has closed almost $208m in series A and project funding.
Life sciences investment firm led what was described at the time as a $180m series A round for Arvelle in February 2019, investing with Andera Partners, BRV Capital Management, NovaQuest and HIG BioHealth Partners.
However, Arvelle has just closed the final tranche of the round, which it said…
